TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells

[1]  J. Kere,et al.  Single‐cell RNA‐seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63 , 2018, Cancer medicine.

[2]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[3]  Bin Wang,et al.  Downregulation of TNFAIP2 suppresses proliferation and metastasis in esophageal squamous cell carcinoma through activation of the Wnt/β-catenin signaling pathway. , 2017, Oncology reports.

[4]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[5]  Eiji Kikuchi,et al.  Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation. , 2016, JCI insight.

[6]  L. Jia,et al.  KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2 , 2016, Oncogene.

[7]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. , 2015, European urology.

[8]  Xiangyin Kong,et al.  Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-like Cell Traits in Breast Cancer. , 2015, Cancer research.

[9]  Chao Zhang,et al.  Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial–mesenchymal transition , 2014, Cell proliferation.

[10]  N. Tsang,et al.  NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein–Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma , 2014, Oncogene.

[11]  Y. Song,et al.  Metadherin regulates proliferation and metastasis via actin cytoskeletal remodelling in non-small cell lung cancer , 2014, British Journal of Cancer.

[12]  G. Zhu,et al.  Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial-mesenchymal transition. , 2014, Cancer letters.

[13]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[14]  Zhao-You Tang,et al.  Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition , 2011, Clinical Cancer Research.

[15]  E. Kikuchi,et al.  Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer , 2011, British Journal of Cancer.

[16]  Haiyang Guo,et al.  Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition , 2011, Cancer science.

[17]  Ying Liang,et al.  A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma , 2011, Modern Pathology.

[18]  Y. Okada,et al.  Imaging , Diagnosis , Prognosis Expression of Snail in Upper Urinary Tract Urothelial Carcinoma : Prognostic Significance and Implications for Tumor Invasion , 2010 .

[19]  C. Dinney,et al.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer , 2009, Cancer and Metastasis Reviews.

[20]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[21]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[22]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[23]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[24]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[25]  E. Ruoslahti,et al.  Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. , 2004, Cancer cell.

[26]  P. Fisher,et al.  Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH , 2002, Oncogene.

[27]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Ross,et al.  Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. , 2000, Cancer research.

[29]  F. W. Wolf,et al.  B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome. , 1994, The Journal of biological chemistry.

[30]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. , 2015, European urology.

[32]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[33]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.